{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"Neuropathy was monitored using Total Neuropathy Score reduced (TNSr).","groups":[{"description":"The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.\n\nbortezomib\n\nthalidomide","id":"OG000","title":"Bortezomib and Thalidomide"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1-6 months","title":"Peripheral Motor and Sensory Neuropathy (Grade 2 and Higher)","type":"SECONDARY","unitOfMeasure":"participants"}